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Other names: ALK-SMase (Alkaline 
sphingomyelinase); E-NPP7; MGC50179; NPP-7 
Location: 17q25.3 
Local order: Upstream to a hypothetical protein 
LOC146743 and downstream to CBX2. 
DNA/RNA 
 
Structure of ENPP7 gene: intron-exon organization 
Description 
The ENPP7 gene is 11.139 bp in length and is 
composed of 6 exons in the size of 1841 bp. The first 
20 bp in exon 1, the last 17 bp in exon 5 and the exon 6 
are not translated. 
Transcription 
Besides the wild type transcript shown above, different 
transcripts have been identified. The first is the one 
with exon 4 deletion, which has been found in HepG2 
liver cancer cells and some human colon and liver 
cancer tissues. The second one also deletes exon 4 but 
inserts 7 foreign amino acids due to the shift of the 
splice site. This transcript was identified in human 
HT29 colon cancer cells. The third one has a larger 
exon 1 than the wild type, which includes upstream 
another starting codon (219 bp upstream), and was 
identified in one liver tumor. Some factors such as 
ursodeoxycholic acid and psyllium have been found to 
stimulate the expression of ENPP7 whereas high fat 






The structure of ENPP7 protein. The regions with green, red, gray, blue and white colors indicate the amino acids coded by different 
exons. The five N-glycosylation sites are shown above the bar and two metal binding sits formed by 6 amino acids are shown under the 
bar. Two hydrophobic domains (from T5 to A22, and P441 to V457) and the predicted catalytic site (T73-H79) are indicated. 
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Protein 
Description 
The wild type ENPP7 contains 458 amino acids, which 
shares 30-36% identity to other members of the NPP 
family. The protein has a signal peptide at the N-
terminal, which is cleaved in the mature enzyme, and a 
transmembrane domain at the C-terminal, which 
anchors the enzyme on the plasma membrane. The rest 
part of the enzyme is located outside the cells. The 
enzyme has 5 N-glycosylation sites and glycosylation 
is important for both transport of the enzyme to the 
plasma membrane and for enzyme activity. Similar to 
other NPP members, ENPP7 has two metal binding 
sites formed by 6 amino acids. These sites are predicted 
to serve as substrate binding site. 
Expression 
The enzyme has so far been found to express in the 
intestinal mucosal cells of many species and 
additionally human liver cells. The expression in liver 
may be restricted to human, because no activity or 
mRNA of ENPP7 could be found in the bile or liver of 
many other species. The expression is associated with 
differentiation of both intestinal and hepatic cells. 
ENPP7 is developed early in the fetus and high activity 
has been found in the meconium of human fetus at the 
age of 23 week gestation. 
Localisation 
The enzyme is localized at the apical part but not 
basolateral part of intestinal epithelial cells. The 
enzyme can be dissociated from the membrane by bile 
salt and by pancreatic trypsin and released into the 
lumen in fully active form. Along the intestinal tract, 
the activity is low in the duodenum, high in the 
jejunum, and rapidly decreasing in the distal part of 
ileum and colon. The enzyme is also found in human 
bile, which is expressed in the liver and released to the 
bile. 
Function 
ENPP7 is a member of the ecto-nucleotide 
pyrophosphatase/phosphodiesterase (NPP) family with 
specific activity against lipids with positively charged 
phosphocholine headgroup including sphingomyelin, 
lysophosphatidylcholine and platelet activating factor 
(PAF). It hydrolyzes sphingomyelin to generate 
ceramide, a potent antiproliferative and proapoptotic 
molecule. It hydrolyzes lysophosphatidylcholine to 
monoglyceride and therefore competes with 
lysophospholipase D to reduce the formation of 
lysophosphatidic acid, a potent factor for inflammation 
and angiogenesis. It hydrolyses PAF to 1-0-alkyl-2-
acetyl-sn-glycerol and inhibits PAF-induced 
inflammatory responses. ENPP7 has been proposed as 
a tumor suppressor protein. 
In addition, ENPP7 may influence cholesterol 
absorption by hydrolyzing sphingomyelin in the 
intestinal lumen and on the apical surface of microvilli, 
as the levels of sphingomyelin in the intestinal tract 
affect cholesterol absorption. 
Homology 
ENPP7 shares 30-35% homology with other members 
of ENPP family. Regard to ENPP7, human ENPP7 
shares 85% identity with rat form (NP_001012484), 
82% with the mouse form (NP_001025462.1), and 82% 
with fowl form (XP 423912.1). The N-glycosylation 
sites, the amino acids forming the metal coordinate 




The figure shows the aberrant transcript forms of ENPP7 identified in colon and liver cancers. The first is the one with deleted exon 4, 
which was found in HepG2 liver cancer cells and human liver cancer and colon cancer tissues. The second is similar as the first one but 
with an insertion of 7 foreign amino acids due to the shift of the splice site. The third one has a larger exon 1 than the wild type, which 
includes another starting codon, and was identified in one liver tumor (not shown in the figure). Formation of these aberrant forms are 
not caused by genomic mutation, but alternative splicing. 
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Implicated in 
Colon cancer, inflammatory bowel 
diseases, and liver cancer 
Disease 
ENPP7 may have implications in colon cancer, 
inflammatory bowel diseases such as ulcerative colitis, 
necrotizing enterocolitis, and liver cancer. Significant 
reduction of ENPP7 activity has been found in human 
longstanding ulcerative colitis, sporadic colon cancer 
and familial adenomatous polyposis The reduction may 
be caused by formation of the aberrant transcripts, 
which cause the inactivation of ENPP7, and have been 
found in human HT29 colon cancer cells, HepG2 liver 
cancer cells and also in human colon and liver cancer 
tissues. The frequency of such mutations is unknown. 
ENPP7 may also affect the pathogenesis of 
atherosclerosis as it influences the sphingomyelin 
levels in the gut and thus affect cholesterol absorption. 
Prognosis 
The enzyme activity is easy to be determined in the 
feces. Fecal activity reflects the total enzyme levels in 
the intestinal tract and has been shown to be decreased 
in colonic inflammation and cancer. 
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